{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:12:23Z","timestamp":1785363143501,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ejca.2018.05.009","type":"journal-article","created":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T10:51:55Z","timestamp":1528973515000},"page":"66-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Clinical and pharmacogenetic determinants of 5-fluorouracyl\/leucovorin\/irinotecan toxicity: Results of\u00a0the PETACC-3 trial"],"prefix":"10.1016","volume":"99","author":[{"given":"Sabine","family":"Tejpar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Piessevaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Brauchli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9914-0243","authenticated-orcid":false,"given":"Dirk","family":"Klingbiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8856-6185","authenticated-orcid":false,"given":"Roberto","family":"Fiocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7631-3263","authenticated-orcid":false,"given":"Mauro","family":"Delorenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Bosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud D.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2018.05.009_bib1","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1023\/A:1008261821434","article-title":"Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports","volume":"8","author":"Wasserman","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.05.009_bib2","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/sj.bjc.6602042","article-title":"UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer","volume":"91","author":"Marcuello","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2018.05.009_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/GIM.0b013e31818efd77","article-title":"Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review","volume":"11","author":"Palomaki","year":"2009","journal-title":"Genet Med"},{"key":"10.1016\/j.ejca.2018.05.009_bib4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2125.2006.02591.x","article-title":"The role of pharmacogenetics in cancer therapeutics","volume":"62","author":"Yong","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ejca.2018.05.009_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/GIM.0b013e31818efd77","article-title":"Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review","volume":"11","author":"Glenn","year":"2009","journal-title":"Genet Med"},{"key":"10.1016\/j.ejca.2018.05.009_bib6","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1200\/JCO.2004.07.173","article-title":"Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan","volume":"22","author":"Innocenti","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.05.009_bib7","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1158\/1055-9965.EPI-07-2517","article-title":"Gilbert's syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk","volume":"17","author":"Lankisch","year":"2008","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"10.1016\/j.ejca.2018.05.009_bib8","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2008.19.0314","article-title":"Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan","volume":"27","author":"Cecchin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.05.009_bib9","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1200\/JCO.2008.20.6300","article-title":"Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics","volume":"27","author":"Innocenti","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.05.009_bib10","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ctrv.2008.05.002","article-title":"Clinical and pharmacogenetic factors associated with irinotecan toxicity","volume":"34","author":"Kweekel","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2018.05.009_bib11","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3892\/ijo.2014.2556","article-title":"A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes","volume":"45","author":"Tsunedomi","year":"2014","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ejca.2018.05.009_bib12","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00008571-199712000-00007","article-title":"Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications","volume":"7","author":"Ciotti","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.ejca.2018.05.009_bib13","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/00008571-200010000-00006","article-title":"Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene","volume":"10","author":"Guillemette","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.ejca.2018.05.009_bib14","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0169-409X(02)00066-2","article-title":"Genetic contribution to variable human CYP3A-mediated metabolism","volume":"54","author":"Lamba","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ejca.2018.05.009_bib15","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/03602530600739835","article-title":"Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan","volume":"38","author":"Nagar","year":"2006","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.ejca.2018.05.009_bib16","doi-asserted-by":"crossref","first-page":"7859","DOI":"10.18632\/oncotarget.23559","article-title":"DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer","volume":"9","author":"Cremolini","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2018.05.009_bib17","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1200\/JCO.2008.21.6663","article-title":"Randomized phase III trial comparing biweekly infusional fluorouracil\/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3","volume":"27","author":"Van Cutsem","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.05.009_bib18","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2307\/2531691","article-title":"A linear rank test for use when the main interest is in differences in cure rates","volume":"45","author":"Gray","year":"1989","journal-title":"Biometrics"},{"key":"10.1016\/j.ejca.2018.05.009_bib19","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/tpj.2013.10","article-title":"Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians","volume":"14","author":"Liu","year":"2014","journal-title":"Pharmacogenom J"},{"key":"10.1016\/j.ejca.2018.05.009_bib20","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/jnci\/djm115","article-title":"UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters","volume":"99","author":"Hoskins","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2018.05.009_bib21","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1200\/JCO.1992.10.7.1171","article-title":"Influence of sex and age on fluorouracil clearance","volume":"10","author":"Milano","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.05.009_bib22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1023\/A:1006456717846","article-title":"Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11","volume":"19","author":"Miya","year":"2001","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ejca.2018.05.009_bib23","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.toxlet.2009.11.017","article-title":"Relations between strain and gender dependencies of irinotecan toxicity and UGT1A1, CES2 and TOP1 expressions in mice","volume":"192","author":"Ahowesso","year":"2010","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.ejca.2018.05.009_bib24","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1158\/1078-0432.CCR-09-1526","article-title":"A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan","volume":"16","author":"van der Bol","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2018.05.009_bib25","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/dmd.113.054833","article-title":"Alteration of the function of the UDP-glucuronosyltransferase 1A subfamily by cytochrome P450 3A4: different susceptibility for UGT isoforms and UGT1A1\/7 variants","volume":"42","author":"Ishii","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ejca.2018.05.009_bib26","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0167-4781(94)00244-W","article-title":"A novel CYP3 gene from female rats","volume":"1260","author":"Strotkamp","year":"1995","journal-title":"Biochim Biophys"},{"key":"10.1016\/j.ejca.2018.05.009_bib27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3109\/03602539808996322","article-title":"Sex-dependent metabolism of xenobiotics","volume":"30","author":"Mugford","year":"1998","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.ejca.2018.05.009_bib28","first-page":"742","article-title":"A model to predict chemotherapy-related severe or febrile neutropenia in cycle one among breast cancer and lymphoma patients","volume":"23","author":"Morrison","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2018.05.009_bib29","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00520-003-0442-z","article-title":"Development and validation of a patient-specific predictive instrument for the need for dose reduction in chemotherapy for breast cancer: a potential decision aid for the use of myeloid growth factors","volume":"11","author":"Savvides","year":"2003","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2018.05.009_bib30","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1200\/JCO.1998.16.7.2392","article-title":"First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy","volume":"16","author":"Silber","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.05.009_bib31","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1200\/JCO.1996.14.2.636","article-title":"Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia","volume":"14","author":"Blay","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.05.009_bib32","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1634\/theoncologist.10-6-427","article-title":"Risk models for predicting chemotherapy-induced neutropenia","volume":"10","author":"Lyman","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2018.05.009_bib33","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00520-010-0840-y","article-title":"Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study","volume":"19","author":"Schwenkglenks","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2018.05.009_bib34","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/jnci\/djm115","article-title":"UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters","volume":"99","author":"Hoskins","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2018.05.009_bib35","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/(SICI)1097-0142(19990215)85:4<786::AID-CNCR5>3.0.CO;2-9","article-title":"A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma","volume":"85","author":"Rothenberg","year":"1999","journal-title":"Cancer"},{"issue":"5 Suppl 2","key":"10.1016\/j.ejca.2018.05.009_bib36","first-page":"S23","article-title":"Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer","volume":"3","author":"Goldberg","year":"2009","journal-title":"Gastrointest Cancer Res: GCR"},{"key":"10.1016\/j.ejca.2018.05.009_bib37","first-page":"S23","article-title":"Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer","volume":"3","author":"Goldberg","year":"2009","journal-title":"Gastrointest Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918308499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918308499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T15:11:10Z","timestamp":1604416270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918308499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":37,"alternative-id":["S0959804918308499"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.05.009","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and pharmacogenetic determinants of 5-fluorouracyl\/leucovorin\/irinotecan toxicity: Results of\u00a0the PETACC-3 trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}